Gosuranemab
- Generic Name
- Gosuranemab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1788032-39-2
- Unique Ingredient Identifier
- 09FZ7Q0PQZ
- Background
Gosuranemab is under investigation in clinical trial NCT02460094 (Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy).
- Associated Conditions
- -
- Associated Therapies
- -
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Biogen
- Target Recruit Count
- 65
- Registration Number
- NCT02294851
- Locations
- 🇺🇸
WCCT Global, LLC, Cypress, California, United States
🇺🇸Covance Clinical Research Unit Inc., Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath